ClinConnect ClinConnect Logo
Search / Trial NCT03887117

Effect of Switching From Cigarette Smoking to IQOS on Exercise Capacity

Launched by PHILIP MORRIS PRODUCTS S.A. · Mar 20, 2019

Trial Information

Current as of May 04, 2025

Completed

Keywords

Iqos Heated Tobacco

ClinConnect Summary

This exploratory study, with healthy adult smokers, was designed without product use restrictions (ad libitum product use) in order to replicate as closely as possible "real life" conditions. Subjects randomized to the cigarette and IQOS arms were asked to buy their own cigarettes or HeatSticks, respectively. Subjects randomized to the smoking abstinence (SA) arm were instructed to stay smoking abstinent until the end of the study. Subjects in the SA arm received smoking abstinence support and, in order to prevent relapse to cigarette smoking during the training program, were also allowed t...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Smoking, healthy subject based on safety laboratory, ECG, spirometry, vital signs, physical examination, medical history and Investigator's assessment.
  • Subject has been smoking for at least three years prior to V1.
  • Subject has been smoking ≥ 10 cigarettes per day over the last 12 months. Smoking status will be verified by a urinary cotinine ≥ 200 ng/mL and CO exhaled breath test \> 10 ppm both at V1 and V2.
  • Subject does not plan to quit smoking within 6 months after V1.
  • Exclusion Criteria:
  • Subject has a clinically relevant disease which requires medication (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, urological, immunological, pulmonary \[such as but not limited to pulmonary oedema, asthma\], and cardiovascular \[such as, but not limited to myocardial infarction, unstable angina, uncontrolled arrhythmias, heart failure\], disease) or any other clinically significant medical condition (including abnormal safety laboratory result as per CTCAE), which as per the judgment of the Investigator would jeopardize the safety of the subject.
  • Subject performs more than 45 min of vigorous physical activity per week.
  • Subject takes medication influencing blood volume such as erythropoietin, diuretics and beta blockers, or diabetic medications.
  • Subject cannot participate in the study for any reason other than medical as per the Investigator's judgment (e.g. psychological and/or social reason)
  • For women only: subject is pregnant (does not have negative pregnancy tests at V1 and at V2) or is breastfeeding.
  • For women of childbearing potential : female subject who does not agree to using an acceptable method of effective contraception during the entire study.
  • Subject has a BMI \< 18.5 kg/m2 or BMI ≥ 30 kg/m2.
  • Subject has a positive urine drug screen.
  • Subject has been previously screened for this study.
  • Subject, or one of their family members (e.g., spouse, parent, sibling or child), is a current or former employee of the tobacco industry.
  • Subject, or one of their family members (e.g. spouse, parent, sibling or child), is an employee of the investigational site or any other parties involved in the study.
  • Subject is legally incompetent, or physically or mentally incapable of giving consent (e.g., emergency situation, under guardianship, prisoners, or subjects who are involuntarily incarcerated).

About Philip Morris Products S.A.

Philip Morris Products S.A. is a leading global tobacco and nicotine product manufacturer, dedicated to transforming its business by developing and promoting smoke-free alternatives. With a strong emphasis on research and innovation, the company invests significantly in scientific studies to understand the health impacts of its products and to explore alternatives that reduce harm associated with traditional smoking. As a responsible industry leader, Philip Morris Products S.A. actively engages in clinical trials to evaluate the safety and efficacy of its reduced-risk products, contributing to the evolving landscape of tobacco harm reduction and public health.

Locations

Mannheim, , Germany

Patients applied

0 patients applied

Trial Officials

Armin Schultz, MD

Principal Investigator

CRS Clinical Research Services Mannheim GmbH

Christelle Haziza, PhD

Study Chair

Philip Morris Products S.A.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials